Faculty ProfilesVivek Jain, MD
Assistant Adjunct Professor
SFGH HIV/AIDS Div., Ward 84
Vivek Jain, M.D., M.A.S. is an assistant professor of medicine and infectious diseases in the HIV/AIDS Division at San Francisco General Hospital, UCSF. He conducts implementation science research on HIV antiretroviral therapy (ART) delivery in resource limited settings, working within collaborations between UCSF and collaborators in Uganda and Kenya. The goal of this research is to develop, test and understand the most optimal ways in which earlier ART can be delivered to affected populations in Sub Saharan Africa. He is also conducting clinical translational research on the immunologic and virologic impact of early versus deferred initiation of HIV antiretroviral therapy. The goal of this research is to better define the optimal time for ART initiation, and to explore and understand the biology of early HIV infection and what impact early-initiated ART exerts on it.
Dr. Jain earned his undergraduate degree in Biochemistry from Harvard University, followed by his M.D. from Stanford University School of Medicine. He completed residency, chief residency, and infectious disease fellowship at UCSF, as well as an M.A.S. degree in clinical research also at UCSF. Dr. Jain serves as an outpatient HIV physician in the Positive Health Practice Clinic at San Francisco General Hospital, and an attending physician on the inpatient infectious disease consult team.
Recent Articles (25)
Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Balzer LB, Petersen ML, Thirumurthy H, Charlebois ED, Kamya MR, Havlir DV. Uptake of Community-Based HIV Testing during a Multi-Disease Health Campaign in Rural Uganda. PLoS One. 2014; 9(1):e84317.
Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, Chamie G, Petersen ML, Thirumurthy H, Kamya MR, Charlebois ED, Havlir DV. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health. 2013 Dec 9; 13(1):1151.
Jain V, Byonanebye DM, Liegler T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng EH, Charlebois ED, Amanyire G, Kamya MR, Havlir DV. Changes in Population HIV RNA Levels in Mbarara, Uganda During Scale-Up of HIV Antiretroviral Therapy Access. J Acquir Immune Defic Syndr. 2013 Oct 1.
Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, Jain V, Clark TD, Charlebois E, Havlir DV, Kamya M, Geng EH. High Retention in Care Among HIV-Infected Patients Entering Care With CD4 Levels >350 cells/µL Under Routine Program Conditions in Uganda. Clin Infect Dis. 2013 Nov; 57(9):1343-50.
Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee TH, Busch MP, McCune JM, Pilcher CD, Hecht FM, Deeks SG. Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. J Infect Dis. 2013 Oct; 208(8):1202-11.
Thirumurthy H, Chamie G, Jain V, Kabami J, Kwarisiima D, Clark TD, Geng E, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda. AIDS. 2013 Feb 20; 27(4):627-34.
Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Assessment of Population-Based HIV RNA Levels in a Rural East African Setting Using a Fingerprick-Based Blood Collection Method. Clin Infect Dis. 2013 Feb; 56(4):598-605.
Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F, Busch MP, Deeks SG. Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T cells. J Infect Dis. 2013 Jul; 208(1):50-6.
Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos KA, Deeks SG, Gandhi M, Havlir DV. The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels Among HIV-Infected Patients Entering Care With a CD4 Count Greater Than 500/µL in a Public Health Setting. Clin Infect Dis. 2012 Dec; 55(12):1690-7.
Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012; 7(8):e43400.
Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011 Apr 15; 203(8):1174-81.
Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One. 2010; 5(12):e15510.
Gayatri NA, Morrall MC, Jain V, Kashyape P, Pysden K, Ferrie C. Parental and physician beliefs regarding the provision and content of written sudden unexpected death in epilepsy (SUDEP) information. Epilepsia. 2010 May; 51(5):777-82.
Jain V, Yang MH, Kovacicova-Lezcano G, Juhle LS, Bolger AF, Winston LG. Infective endocarditis in an urban medical center: association of individual drugs with valvular involvement. J Infect. 2008 Aug; 57(2):132-8.
Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, Jain V, Cunliffe NA, Nakagomi O, Kirkwood CD, Fischer TK, Parashar UD, Bresee JS, Jiang B, Glass RI. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis. 2005 Sep 1; 192 Suppl 1:S146-59.
Clark HF, Lawley DA, Schaffer A, Patacsil JM, Marcello AE, Glass RI, Jain V, Gentsch J. Assessment of the epidemic potential of a new strain of rotavirus associated with the novel G9 serotype which caused an outbreak in the United States for the first time in the 1995-1996 season. J Clin Microbiol. 2004 Apr; 42(4):1434-8.
Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, Xu A, Leidich R, Radziejewska E, Rafique A, Goldberg J, Jain V, Bailey K, Karow M, Fandl J, Samuelsson SJ, Ioffe E, Rudge JS, Daly TJ, Radziejewski C, Yancopoulos GD. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol. 2003 Jan; 10(1):38-44.
Jain V, Mekalanos JJ. Use of lambda phage S and R gene products in an inducible lysis system for Vibrio cholerae- and Salmonella enterica serovar typhimurium-based DNA vaccine delivery systems. Infect Immun. 2000 Feb; 68(2):986-9.
Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996 Dec 27; 87(7):1161-9.